Lee Newman
Concepts (553)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Occupational Health | 34 | 2025 | 209 | 13.900 |
Why?
| | Occupational Exposure | 35 | 2025 | 354 | 7.270 |
Why?
| | Farmers | 15 | 2025 | 69 | 7.130 |
Why?
| | Small Business | 14 | 2022 | 51 | 7.030 |
Why?
| | Saccharum | 16 | 2025 | 77 | 6.890 |
Why?
| | Heat Stress Disorders | 12 | 2025 | 84 | 5.280 |
Why?
| | Berylliosis | 37 | 2018 | 202 | 5.240 |
Why?
| | Hot Temperature | 13 | 2025 | 405 | 4.730 |
Why?
| | Beryllium | 31 | 2018 | 161 | 4.450 |
Why?
| | Renal Insufficiency, Chronic | 15 | 2025 | 653 | 4.030 |
Why?
| | Occupational Injuries | 7 | 2023 | 45 | 3.480 |
Why?
| | Workplace | 26 | 2024 | 274 | 3.470 |
Why?
| | Agricultural Workers' Diseases | 6 | 2025 | 30 | 3.390 |
Why?
| | Occupational Diseases | 11 | 2025 | 164 | 3.190 |
Why?
| | Guatemala | 19 | 2025 | 345 | 2.580 |
Why?
| | Health Promotion | 12 | 2024 | 774 | 2.500 |
Why?
| | Agriculture | 7 | 2024 | 104 | 2.260 |
Why?
| | Leadership | 7 | 2025 | 408 | 1.990 |
Why?
| | Kidney | 10 | 2025 | 1495 | 1.850 |
Why?
| | Workers' Compensation | 4 | 2019 | 28 | 1.770 |
Why?
| | Organizational Culture | 6 | 2024 | 162 | 1.660 |
Why?
| | Creatinine | 8 | 2025 | 505 | 1.490 |
Why?
| | Sarcoidosis | 13 | 2012 | 160 | 1.350 |
Why?
| | Safety Management | 6 | 2021 | 121 | 1.280 |
Why?
| | Humans | 150 | 2025 | 144261 | 1.270 |
Why?
| | Adult | 69 | 2025 | 40262 | 1.270 |
Why?
| | Glomerular Filtration Rate | 5 | 2021 | 758 | 1.270 |
Why?
| | Chronic Disease | 28 | 2025 | 1812 | 1.130 |
Why?
| | Occupational Medicine | 2 | 2025 | 13 | 1.120 |
Why?
| | Population Surveillance | 4 | 2025 | 483 | 1.080 |
Why?
| | Longitudinal Studies | 13 | 2025 | 2926 | 1.070 |
Why?
| | Dehydration | 5 | 2025 | 56 | 1.070 |
Why?
| | Male | 83 | 2025 | 72035 | 1.060 |
Why?
| | Body Temperature | 2 | 2025 | 228 | 1.040 |
Why?
| | Absenteeism | 2 | 2018 | 52 | 1.040 |
Why?
| | Middle Aged | 63 | 2025 | 35762 | 1.000 |
Why?
| | Health Behavior | 5 | 2022 | 782 | 0.990 |
Why?
| | Heat-Shock Response | 2 | 2025 | 77 | 0.990 |
Why?
| | Lymphocytes | 4 | 2018 | 382 | 0.980 |
Why?
| | Biomarkers | 8 | 2024 | 4254 | 0.960 |
Why?
| | Kidney Diseases | 3 | 2025 | 425 | 0.910 |
Why?
| | HSP70 Heat-Shock Proteins | 3 | 2024 | 75 | 0.900 |
Why?
| | Industry | 4 | 2019 | 43 | 0.870 |
Why?
| | Efficiency | 3 | 2024 | 103 | 0.870 |
Why?
| | Inservice Training | 1 | 2025 | 116 | 0.850 |
Why?
| | Colorado | 19 | 2023 | 4562 | 0.850 |
Why?
| | Body Temperature Regulation | 1 | 2025 | 107 | 0.830 |
Why?
| | Inhalation Exposure | 2 | 2025 | 115 | 0.810 |
Why?
| | Air Pollution | 2 | 2025 | 326 | 0.780 |
Why?
| | Environmental Monitoring | 6 | 2025 | 377 | 0.760 |
Why?
| | Developing Countries | 1 | 2025 | 314 | 0.750 |
Why?
| | Point-of-Care Testing | 2 | 2023 | 35 | 0.750 |
Why?
| | Occupational Stress | 1 | 2023 | 46 | 0.740 |
Why?
| | Air Pollutants | 4 | 2020 | 438 | 0.700 |
Why?
| | Female | 67 | 2025 | 77976 | 0.690 |
Why?
| | Acute Kidney Injury | 2 | 2019 | 862 | 0.660 |
Why?
| | Neurophysins | 1 | 2020 | 5 | 0.640 |
Why?
| | Tobacco Smoke Pollution | 2 | 2021 | 233 | 0.640 |
Why?
| | Arsenic | 1 | 2021 | 66 | 0.630 |
Why?
| | Mexico | 3 | 2025 | 233 | 0.620 |
Why?
| | Risk Factors | 24 | 2025 | 10699 | 0.620 |
Why?
| | Anemia | 1 | 2021 | 187 | 0.620 |
Why?
| | Capacity Building | 1 | 2020 | 58 | 0.620 |
Why?
| | Glycopeptides | 1 | 2020 | 44 | 0.620 |
Why?
| | Analgesics, Opioid | 2 | 2018 | 1131 | 0.610 |
Why?
| | Vasopressins | 1 | 2020 | 60 | 0.610 |
Why?
| | HLA-DP Antigens | 6 | 2011 | 32 | 0.610 |
Why?
| | Respiratory Hypersensitivity | 4 | 2004 | 65 | 0.600 |
Why?
| | Protein Precursors | 1 | 2020 | 136 | 0.590 |
Why?
| | Program Evaluation | 4 | 2025 | 946 | 0.580 |
Why?
| | Cross-Sectional Studies | 12 | 2021 | 5813 | 0.580 |
Why?
| | Presenteeism | 1 | 2018 | 6 | 0.570 |
Why?
| | Young Adult | 15 | 2025 | 13990 | 0.570 |
Why?
| | Particulate Matter | 4 | 2025 | 347 | 0.570 |
Why?
| | Smoking | 8 | 2021 | 1468 | 0.560 |
Why?
| | Latin America | 3 | 2025 | 93 | 0.560 |
Why?
| | Veterinarians | 1 | 2018 | 11 | 0.560 |
Why?
| | Cell Proliferation | 5 | 2018 | 2494 | 0.560 |
Why?
| | Mass Screening | 4 | 2025 | 1332 | 0.550 |
Why?
| | Drug Utilization | 1 | 2018 | 166 | 0.540 |
Why?
| | Accidents, Occupational | 2 | 2015 | 14 | 0.540 |
Why?
| | Sleep | 2 | 2023 | 901 | 0.530 |
Why?
| | CD4-Positive T-Lymphocytes | 13 | 2011 | 1128 | 0.530 |
Why?
| | Body Composition | 1 | 2021 | 704 | 0.530 |
Why?
| | Text Messaging | 1 | 2020 | 181 | 0.520 |
Why?
| | Clinical Laboratory Techniques | 1 | 2018 | 96 | 0.520 |
Why?
| | Extraction and Processing Industry | 2 | 2014 | 9 | 0.520 |
Why?
| | Health Personnel | 1 | 2024 | 742 | 0.510 |
Why?
| | Work Performance | 1 | 2017 | 7 | 0.510 |
Why?
| | Professional Role | 1 | 2018 | 158 | 0.510 |
Why?
| | Mental Health | 1 | 2024 | 776 | 0.510 |
Why?
| | Metabolic Diseases | 1 | 2018 | 113 | 0.510 |
Why?
| | Employment | 3 | 2025 | 185 | 0.500 |
Why?
| | Guidelines as Topic | 1 | 2018 | 267 | 0.490 |
Why?
| | Lymphocyte Activation | 17 | 2014 | 1126 | 0.490 |
Why?
| | Renal Insufficiency | 1 | 2018 | 168 | 0.490 |
Why?
| | Environmental Exposure | 8 | 2013 | 587 | 0.480 |
Why?
| | Federal Government | 1 | 2016 | 23 | 0.480 |
Why?
| | Health Policy | 1 | 2019 | 398 | 0.470 |
Why?
| | Food Industry | 1 | 2015 | 8 | 0.460 |
Why?
| | Hypertension | 2 | 2025 | 1254 | 0.460 |
Why?
| | Sarcoidosis, Pulmonary | 8 | 2010 | 95 | 0.450 |
Why?
| | CpG Islands | 1 | 2015 | 165 | 0.450 |
Why?
| | Antigens, Bacterial | 4 | 2012 | 125 | 0.450 |
Why?
| | Tumor Necrosis Factor-alpha | 5 | 2015 | 1217 | 0.450 |
Why?
| | Safety | 2 | 2015 | 355 | 0.440 |
Why?
| | United States | 17 | 2025 | 15876 | 0.440 |
Why?
| | Prevalence | 4 | 2025 | 2815 | 0.420 |
Why?
| | Occupational Health Services | 1 | 2014 | 36 | 0.420 |
Why?
| | Guideline Adherence | 1 | 2018 | 586 | 0.410 |
Why?
| | Chronic Pain | 1 | 2018 | 290 | 0.410 |
Why?
| | Oil and Gas Fields | 1 | 2014 | 33 | 0.410 |
Why?
| | Pulmonary Fibrosis | 3 | 2005 | 395 | 0.400 |
Why?
| | Cancer Survivors | 3 | 2025 | 326 | 0.400 |
Why?
| | Natural Gas | 4 | 2014 | 26 | 0.390 |
Why?
| | Granuloma, Respiratory Tract | 4 | 2007 | 13 | 0.390 |
Why?
| | Lung | 12 | 2019 | 4108 | 0.380 |
Why?
| | Life Style | 1 | 2015 | 475 | 0.370 |
Why?
| | Risk Reduction Behavior | 1 | 2014 | 225 | 0.360 |
Why?
| | Influenza, Human | 2 | 2022 | 615 | 0.350 |
Why?
| | Mycobacterium | 3 | 2009 | 116 | 0.350 |
Why?
| | Air Pollutants, Occupational | 4 | 2025 | 42 | 0.340 |
Why?
| | Aged | 24 | 2025 | 25850 | 0.340 |
Why?
| | Cost-Benefit Analysis | 1 | 2014 | 623 | 0.340 |
Why?
| | Promoter Regions, Genetic | 1 | 2015 | 1255 | 0.330 |
Why?
| | Mass Spectrometry | 1 | 2014 | 744 | 0.330 |
Why?
| | Mycobacterium Infections | 2 | 2012 | 61 | 0.330 |
Why?
| | Logistic Models | 7 | 2022 | 2104 | 0.320 |
Why?
| | DNA Methylation | 1 | 2015 | 681 | 0.320 |
Why?
| | Opioid-Related Disorders | 1 | 2018 | 576 | 0.320 |
Why?
| | Macrophages, Alveolar | 2 | 2004 | 368 | 0.320 |
Why?
| | HLA-DP beta-Chains | 7 | 2014 | 87 | 0.320 |
Why?
| | Ferritins | 2 | 2014 | 69 | 0.310 |
Why?
| | Air Pollution, Indoor | 3 | 2019 | 181 | 0.310 |
Why?
| | Electrolytes | 2 | 2020 | 55 | 0.310 |
Why?
| | Practice Patterns, Physicians' | 1 | 2018 | 1347 | 0.300 |
Why?
| | Macrophages | 2 | 2015 | 1510 | 0.300 |
Why?
| | Mental Disorders | 1 | 2018 | 1138 | 0.290 |
Why?
| | Data Collection | 1 | 2011 | 633 | 0.290 |
Why?
| | Health Status | 3 | 2021 | 833 | 0.290 |
Why?
| | HLA Antigens | 4 | 2010 | 225 | 0.290 |
Why?
| | Delivery of Health Care | 1 | 2016 | 940 | 0.290 |
Why?
| | B-Lymphocytes | 1 | 2014 | 876 | 0.280 |
Why?
| | Multivariate Analysis | 6 | 2018 | 1533 | 0.280 |
Why?
| | Perception | 3 | 2021 | 377 | 0.280 |
Why?
| | Temperature | 2 | 2023 | 678 | 0.280 |
Why?
| | Sensitivity and Specificity | 8 | 2023 | 1983 | 0.280 |
Why?
| | HLA-DR Antigens | 7 | 2010 | 220 | 0.280 |
Why?
| | T-Lymphocytes | 3 | 2014 | 1982 | 0.270 |
Why?
| | Insurance Claim Reporting | 2 | 2018 | 25 | 0.270 |
Why?
| | Immunization | 3 | 2005 | 374 | 0.270 |
Why?
| | Time Factors | 5 | 2025 | 7155 | 0.260 |
Why?
| | Program Development | 2 | 2020 | 369 | 0.260 |
Why?
| | Police | 1 | 2007 | 45 | 0.260 |
Why?
| | Genetic Predisposition to Disease | 8 | 2010 | 2359 | 0.260 |
Why?
| | Respiratory Protective Devices | 2 | 2007 | 15 | 0.250 |
Why?
| | Methamphetamine | 1 | 2007 | 68 | 0.250 |
Why?
| | Apoptosis | 4 | 2005 | 2430 | 0.250 |
Why?
| | Wyoming | 2 | 2018 | 27 | 0.250 |
Why?
| | Internet | 1 | 2011 | 698 | 0.250 |
Why?
| | Case-Control Studies | 10 | 2018 | 3592 | 0.240 |
Why?
| | Spectrometry, Mass, Secondary Ion | 1 | 2005 | 2 | 0.240 |
Why?
| | Central Nervous System Stimulants | 1 | 2007 | 182 | 0.230 |
Why?
| | Prospective Studies | 5 | 2020 | 7970 | 0.230 |
Why?
| | Plutonium | 1 | 2005 | 4 | 0.230 |
Why?
| | Neopterin | 2 | 2003 | 13 | 0.230 |
Why?
| | Incidence | 3 | 2025 | 2870 | 0.230 |
Why?
| | Chemical Industry | 1 | 2005 | 8 | 0.230 |
Why?
| | Bronchoalveolar Lavage Fluid | 9 | 2009 | 636 | 0.230 |
Why?
| | alpha 1-Antitrypsin Deficiency | 1 | 2006 | 59 | 0.230 |
Why?
| | Organism Hydration Status | 1 | 2025 | 9 | 0.230 |
Why?
| | Cohort Studies | 6 | 2019 | 5935 | 0.220 |
Why?
| | Antigen Presentation | 4 | 2014 | 205 | 0.220 |
Why?
| | Climate Change | 3 | 2023 | 199 | 0.220 |
Why?
| | Pilot Projects | 2 | 2021 | 1867 | 0.220 |
Why?
| | Research | 3 | 2018 | 428 | 0.220 |
Why?
| | Neoplasms | 5 | 2025 | 2870 | 0.220 |
Why?
| | Nuclear Warfare | 1 | 2004 | 10 | 0.220 |
Why?
| | Proteomics | 2 | 2011 | 1191 | 0.220 |
Why?
| | Humidity | 1 | 2024 | 52 | 0.210 |
Why?
| | Pandemics | 3 | 2022 | 1682 | 0.210 |
Why?
| | Cadmium | 2 | 2022 | 68 | 0.210 |
Why?
| | Diabetes Mellitus | 2 | 2025 | 1092 | 0.210 |
Why?
| | Age of Onset | 1 | 2006 | 536 | 0.210 |
Why?
| | Research Design | 2 | 2022 | 1129 | 0.200 |
Why?
| | Prognosis | 6 | 2020 | 4278 | 0.200 |
Why?
| | Electronic Health Records | 1 | 2011 | 1169 | 0.200 |
Why?
| | Risk Assessment | 5 | 2021 | 3637 | 0.190 |
Why?
| | Pneumoconiosis | 2 | 2004 | 20 | 0.190 |
Why?
| | Vaccination | 1 | 2011 | 1422 | 0.190 |
Why?
| | Volcanic Eruptions | 1 | 2022 | 5 | 0.190 |
Why?
| | Inflammation Mediators | 3 | 2014 | 508 | 0.190 |
Why?
| | Residence Characteristics | 2 | 2018 | 376 | 0.190 |
Why?
| | Ventilation | 2 | 2019 | 46 | 0.180 |
Why?
| | Receptors, Fibroblast Growth Factor | 1 | 2002 | 69 | 0.180 |
Why?
| | Lymphangioleiomyomatosis | 1 | 2002 | 36 | 0.180 |
Why?
| | Nephrology | 1 | 2023 | 60 | 0.180 |
Why?
| | Immunity, Active | 1 | 2002 | 8 | 0.180 |
Why?
| | Metals, Heavy | 1 | 2022 | 31 | 0.180 |
Why?
| | Antibodies | 1 | 2024 | 401 | 0.180 |
Why?
| | Crops, Agricultural | 2 | 2019 | 31 | 0.180 |
Why?
| | Histocompatibility Antigens Class II | 1 | 2003 | 364 | 0.180 |
Why?
| | Respiratory Function Tests | 5 | 2019 | 546 | 0.180 |
Why?
| | Information Dissemination | 1 | 2024 | 220 | 0.180 |
Why?
| | Health Surveys | 2 | 2018 | 510 | 0.180 |
Why?
| | Metals | 2 | 2004 | 142 | 0.180 |
Why?
| | Models, Immunological | 1 | 2002 | 100 | 0.170 |
Why?
| | Calculi | 1 | 2021 | 16 | 0.170 |
Why?
| | Organizational Innovation | 1 | 2022 | 120 | 0.170 |
Why?
| | Focus Groups | 1 | 2024 | 569 | 0.170 |
Why?
| | Cotinine | 1 | 2021 | 79 | 0.170 |
Why?
| | Medical Oncology | 1 | 2024 | 331 | 0.170 |
Why?
| | Respiratory Tract Infections | 1 | 2006 | 396 | 0.170 |
Why?
| | Fibroblast Growth Factors | 1 | 2002 | 188 | 0.170 |
Why?
| | Nickel | 1 | 2021 | 64 | 0.160 |
Why?
| | Policy | 1 | 2021 | 146 | 0.160 |
Why?
| | Beverages | 1 | 2020 | 69 | 0.160 |
Why?
| | Aged, 80 and over | 8 | 2011 | 8243 | 0.160 |
Why?
| | Virus Diseases | 1 | 2022 | 216 | 0.160 |
Why?
| | Noise, Occupational | 1 | 2019 | 4 | 0.160 |
Why?
| | Transcription, Genetic | 1 | 2006 | 1495 | 0.150 |
Why?
| | HLA-DQ Antigens | 4 | 2010 | 173 | 0.150 |
Why?
| | Kidney Function Tests | 1 | 2020 | 157 | 0.150 |
Why?
| | Sri Lanka | 1 | 2019 | 7 | 0.150 |
Why?
| | Specific Gravity | 1 | 2019 | 11 | 0.150 |
Why?
| | Central America | 1 | 2019 | 24 | 0.150 |
Why?
| | Hemoglobins | 1 | 2021 | 383 | 0.150 |
Why?
| | Nutritional Status | 1 | 2021 | 354 | 0.140 |
Why?
| | Blood Proteins | 2 | 2011 | 249 | 0.140 |
Why?
| | Climate | 1 | 2019 | 89 | 0.140 |
Why?
| | India | 1 | 2019 | 218 | 0.140 |
Why?
| | Social Support | 1 | 2023 | 649 | 0.140 |
Why?
| | Unemployment | 1 | 2018 | 41 | 0.140 |
Why?
| | Interferon-gamma | 5 | 2015 | 784 | 0.140 |
Why?
| | Work Capacity Evaluation | 1 | 2018 | 11 | 0.140 |
Why?
| | Global Health | 2 | 2016 | 394 | 0.140 |
Why?
| | Headache Disorders | 1 | 2018 | 19 | 0.140 |
Why?
| | Digestive System Diseases | 1 | 2018 | 27 | 0.140 |
Why?
| | Cytokines | 4 | 2014 | 2061 | 0.140 |
Why?
| | False Positive Reactions | 1 | 2018 | 121 | 0.140 |
Why?
| | Models, Psychological | 1 | 2020 | 296 | 0.140 |
Why?
| | Asbestosis | 2 | 2011 | 13 | 0.140 |
Why?
| | Urologic Diseases | 1 | 2018 | 40 | 0.140 |
Why?
| | Granuloma | 2 | 2014 | 96 | 0.140 |
Why?
| | Allopurinol | 1 | 2018 | 69 | 0.140 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 1 | 2006 | 919 | 0.140 |
Why?
| | Survivorship | 1 | 2018 | 54 | 0.140 |
Why?
| | Reference Standards | 1 | 2018 | 177 | 0.140 |
Why?
| | Educational Status | 1 | 2020 | 464 | 0.140 |
Why?
| | Benchmarking | 1 | 2019 | 188 | 0.140 |
Why?
| | Adolescent | 7 | 2021 | 22281 | 0.140 |
Why?
| | Musculoskeletal Pain | 1 | 2018 | 43 | 0.140 |
Why?
| | Catalase | 2 | 2009 | 130 | 0.140 |
Why?
| | Physical Exertion | 1 | 2019 | 207 | 0.130 |
Why?
| | Body Mass Index | 2 | 2018 | 2420 | 0.130 |
Why?
| | Fever | 1 | 2019 | 311 | 0.130 |
Why?
| | Lung Diseases, Interstitial | 1 | 2004 | 659 | 0.130 |
Why?
| | Adaptation, Physiological | 1 | 2022 | 569 | 0.130 |
Why?
| | Arthritis | 1 | 2018 | 96 | 0.130 |
Why?
| | Awareness | 1 | 2018 | 106 | 0.130 |
Why?
| | Job Satisfaction | 1 | 2020 | 240 | 0.130 |
Why?
| | Epidemics | 1 | 2018 | 98 | 0.130 |
Why?
| | Hyperthermia, Induced | 1 | 2018 | 121 | 0.130 |
Why?
| | Self Report | 1 | 2021 | 863 | 0.130 |
Why?
| | Respiratory Tract Diseases | 1 | 2018 | 175 | 0.120 |
Why?
| | Antibodies, Monoclonal | 3 | 2012 | 1519 | 0.120 |
Why?
| | Drug Prescriptions | 1 | 2018 | 280 | 0.120 |
Why?
| | Nuclear Energy | 1 | 2016 | 2 | 0.120 |
Why?
| | Nuclear Power Plants | 1 | 2016 | 3 | 0.120 |
Why?
| | Community Health Planning | 1 | 2016 | 41 | 0.120 |
Why?
| | Diagnosis, Differential | 4 | 2004 | 1487 | 0.120 |
Why?
| | Public-Private Sector Partnerships | 1 | 2016 | 44 | 0.120 |
Why?
| | Hypersensitivity | 2 | 2012 | 252 | 0.120 |
Why?
| | HLA-DRB1 Chains | 6 | 2010 | 109 | 0.120 |
Why?
| | Immunity, Innate | 1 | 2002 | 846 | 0.120 |
Why?
| | Fibroblast Growth Factor 2 | 1 | 1996 | 92 | 0.120 |
Why?
| | Proportional Hazards Models | 1 | 2019 | 1322 | 0.120 |
Why?
| | Population Health | 1 | 2016 | 44 | 0.110 |
Why?
| | Linear Models | 1 | 2018 | 850 | 0.110 |
Why?
| | Cell Line, Transformed | 2 | 2014 | 140 | 0.110 |
Why?
| | Cell Line | 2 | 2015 | 2879 | 0.110 |
Why?
| | Mice | 8 | 2019 | 18329 | 0.110 |
Why?
| | Motivation | 1 | 2020 | 605 | 0.110 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2024 | 1409 | 0.110 |
Why?
| | Medical Laboratory Personnel | 2 | 2006 | 6 | 0.110 |
Why?
| | Recurrence | 1 | 2018 | 1134 | 0.110 |
Why?
| | Radiography, Thoracic | 4 | 2006 | 171 | 0.110 |
Why?
| | Heart Diseases | 1 | 2018 | 349 | 0.110 |
Why?
| | Liver Diseases | 1 | 2018 | 304 | 0.110 |
Why?
| | Macrophage Activation | 1 | 2015 | 193 | 0.110 |
Why?
| | Enzyme Inhibitors | 1 | 2018 | 824 | 0.110 |
Why?
| | Mast Cells | 1 | 1996 | 146 | 0.110 |
Why?
| | Community Health Services | 1 | 2016 | 232 | 0.100 |
Why?
| | Ions | 1 | 2014 | 71 | 0.100 |
Why?
| | Disease Progression | 5 | 2011 | 2840 | 0.100 |
Why?
| | Fruit | 1 | 2015 | 152 | 0.100 |
Why?
| | Allergens | 3 | 2006 | 384 | 0.100 |
Why?
| | Research Personnel | 1 | 2016 | 183 | 0.100 |
Why?
| | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2 | 2011 | 143 | 0.100 |
Why?
| | Endotoxins | 2 | 2006 | 220 | 0.100 |
Why?
| | Communication | 1 | 2020 | 961 | 0.100 |
Why?
| | Vegetables | 1 | 2015 | 170 | 0.100 |
Why?
| | Immunologic Memory | 3 | 2005 | 366 | 0.100 |
Why?
| | Community-Based Participatory Research | 2 | 2025 | 166 | 0.100 |
Why?
| | Health Impact Assessment | 1 | 2013 | 8 | 0.100 |
Why?
| | Genotype | 6 | 2011 | 1833 | 0.100 |
Why?
| | Models, Biological | 1 | 2021 | 1820 | 0.100 |
Why?
| | Retrospective Studies | 4 | 2020 | 17009 | 0.100 |
Why?
| | Cell Division | 2 | 2004 | 766 | 0.090 |
Why?
| | Water Supply | 2 | 2016 | 88 | 0.090 |
Why?
| | Maximum Allowable Concentration | 2 | 2019 | 16 | 0.090 |
Why?
| | Sex Factors | 1 | 2018 | 2096 | 0.090 |
Why?
| | Up-Regulation | 2 | 2006 | 851 | 0.090 |
Why?
| | Hydrocarbons | 1 | 2012 | 31 | 0.090 |
Why?
| | Antigens, Fungal | 1 | 2012 | 28 | 0.090 |
Why?
| | Paper | 1 | 2011 | 9 | 0.090 |
Why?
| | Health Services Research | 1 | 2014 | 394 | 0.090 |
Why?
| | Personnel, Hospital | 1 | 2011 | 31 | 0.090 |
Why?
| | T-Lymphocyte Subsets | 2 | 2005 | 415 | 0.090 |
Why?
| | Vital Capacity | 2 | 2019 | 290 | 0.090 |
Why?
| | Bacterial Proteins | 2 | 2009 | 954 | 0.090 |
Why?
| | Pulmonary Gas Exchange | 2 | 2004 | 119 | 0.080 |
Why?
| | Forced Expiratory Volume | 2 | 2019 | 448 | 0.080 |
Why?
| | Liver | 2 | 2018 | 1884 | 0.080 |
Why?
| | Glutamic Acid | 2 | 2003 | 251 | 0.080 |
Why?
| | Schools, Veterinary | 1 | 2010 | 3 | 0.080 |
Why?
| | Practice Guidelines as Topic | 1 | 2018 | 1559 | 0.080 |
Why?
| | Alleles | 4 | 2011 | 878 | 0.080 |
Why?
| | Gene Expression Regulation | 2 | 2019 | 2603 | 0.080 |
Why?
| | Genes, MHC Class II | 1 | 2010 | 76 | 0.080 |
Why?
| | Mesalamine | 1 | 2009 | 9 | 0.080 |
Why?
| | Sulfasalazine | 1 | 2009 | 22 | 0.080 |
Why?
| | Phenotype | 3 | 2010 | 3157 | 0.080 |
Why?
| | Animals | 10 | 2019 | 38030 | 0.080 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2012 | 338 | 0.070 |
Why?
| | Cell Separation | 2 | 2009 | 307 | 0.070 |
Why?
| | Substance-Related Disorders | 1 | 2018 | 1054 | 0.070 |
Why?
| | Uveitis | 1 | 2010 | 148 | 0.070 |
Why?
| | Silicosis | 1 | 1989 | 30 | 0.070 |
Why?
| | Latent Tuberculosis | 1 | 2009 | 71 | 0.070 |
Why?
| | Receptors, Antigen, T-Cell | 2 | 2004 | 668 | 0.070 |
Why?
| | Swimming Pools | 1 | 2007 | 7 | 0.070 |
Why?
| | Hydrotherapy | 1 | 2007 | 7 | 0.070 |
Why?
| | Alcohol Drinking | 1 | 2015 | 812 | 0.070 |
Why?
| | Crime | 1 | 2007 | 60 | 0.070 |
Why?
| | Animal Technicians | 2 | 2006 | 2 | 0.060 |
Why?
| | Spirometry | 3 | 2019 | 230 | 0.060 |
Why?
| | Severity of Illness Index | 4 | 2007 | 2917 | 0.060 |
Why?
| | Water Microbiology | 1 | 2007 | 90 | 0.060 |
Why?
| | RNA, Messenger | 2 | 2006 | 2829 | 0.060 |
Why?
| | Influenza Vaccines | 1 | 2011 | 529 | 0.060 |
Why?
| | Tomography, X-Ray Computed | 1 | 1997 | 2730 | 0.060 |
Why?
| | Cells, Cultured | 5 | 2009 | 4146 | 0.060 |
Why?
| | Aerosols | 1 | 2007 | 186 | 0.060 |
Why?
| | Biopsy | 3 | 2005 | 1075 | 0.060 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2007 | 177 | 0.060 |
Why?
| | Genetic Markers | 2 | 2010 | 331 | 0.060 |
Why?
| | Transcription Factor AP-1 | 1 | 2006 | 79 | 0.060 |
Why?
| | Gene Dosage | 1 | 2006 | 148 | 0.060 |
Why?
| | Reactive Oxygen Species | 2 | 2008 | 621 | 0.060 |
Why?
| | Polymorphism, Genetic | 2 | 2010 | 612 | 0.060 |
Why?
| | Risk | 2 | 2007 | 909 | 0.060 |
Why?
| | RNA Precursors | 1 | 2006 | 156 | 0.060 |
Why?
| | Biopsy, Needle | 2 | 2002 | 183 | 0.060 |
Why?
| | Chromosomes, Human, X | 1 | 2005 | 76 | 0.050 |
Why?
| | Leukocytes, Mononuclear | 2 | 2006 | 573 | 0.050 |
Why?
| | Immunosuppressive Agents | 1 | 2009 | 846 | 0.050 |
Why?
| | Genetic Linkage | 1 | 2005 | 273 | 0.050 |
Why?
| | Radioisotopes | 1 | 2004 | 33 | 0.050 |
Why?
| | Psychological Tests | 1 | 2005 | 131 | 0.050 |
Why?
| | fas Receptor | 1 | 2004 | 92 | 0.050 |
Why?
| | HLA-DRB3 Chains | 1 | 2003 | 2 | 0.050 |
Why?
| | HLA-DRB5 Chains | 1 | 2003 | 2 | 0.050 |
Why?
| | Antioxidants | 1 | 2008 | 549 | 0.050 |
Why?
| | HLA-DRB4 Chains | 1 | 2003 | 6 | 0.050 |
Why?
| | HLA-DQ beta-Chains | 1 | 2003 | 57 | 0.050 |
Why?
| | Odds Ratio | 3 | 2014 | 1072 | 0.050 |
Why?
| | Radiation Dosage | 1 | 2005 | 192 | 0.050 |
Why?
| | Phagocytes | 1 | 2004 | 81 | 0.050 |
Why?
| | Biomarkers, Tumor | 1 | 2011 | 1313 | 0.050 |
Why?
| | CD28 Antigens | 1 | 2003 | 58 | 0.050 |
Why?
| | Chi-Square Distribution | 1 | 2004 | 527 | 0.050 |
Why?
| | Tuberculosis | 1 | 2006 | 289 | 0.050 |
Why?
| | Immunologic Tests | 1 | 2003 | 15 | 0.050 |
Why?
| | Public Health | 2 | 2022 | 564 | 0.050 |
Why?
| | Animals, Laboratory | 1 | 2003 | 21 | 0.050 |
Why?
| | Kinetics | 1 | 2006 | 1627 | 0.050 |
Why?
| | Treatment Outcome | 3 | 2014 | 11643 | 0.050 |
Why?
| | Physiological Phenomena | 1 | 2002 | 3 | 0.050 |
Why?
| | Lipopolysaccharides | 1 | 2006 | 863 | 0.050 |
Why?
| | Culture Techniques | 1 | 2002 | 67 | 0.050 |
Why?
| | NF-kappa B | 1 | 2006 | 661 | 0.050 |
Why?
| | Exercise | 1 | 2015 | 2193 | 0.050 |
Why?
| | Contraindications | 1 | 2002 | 91 | 0.050 |
Why?
| | Disposable Equipment | 1 | 2002 | 24 | 0.050 |
Why?
| | Radiography | 2 | 2003 | 842 | 0.050 |
Why?
| | In Situ Nick-End Labeling | 1 | 2002 | 121 | 0.050 |
Why?
| | Genetic Variation | 1 | 2007 | 982 | 0.050 |
Why?
| | Patch Tests | 1 | 2002 | 57 | 0.040 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2002 | 87 | 0.040 |
Why?
| | Epitopes | 1 | 2003 | 485 | 0.040 |
Why?
| | Statistics, Nonparametric | 1 | 2002 | 427 | 0.040 |
Why?
| | Nuclear Proteins | 1 | 2006 | 748 | 0.040 |
Why?
| | Oxygen Consumption | 1 | 2004 | 724 | 0.040 |
Why?
| | Nuclear Weapons | 2 | 2011 | 7 | 0.040 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2003 | 850 | 0.040 |
Why?
| | Reference Values | 1 | 2002 | 797 | 0.040 |
Why?
| | Point-of-Care Systems | 1 | 2023 | 187 | 0.040 |
Why?
| | Equipment Design | 1 | 2002 | 530 | 0.040 |
Why?
| | Exercise Test | 1 | 2003 | 634 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2004 | 2026 | 0.040 |
Why?
| | 2,4-Dinitrophenol | 1 | 2019 | 9 | 0.040 |
Why?
| | ROC Curve | 2 | 2003 | 612 | 0.040 |
Why?
| | Hearing Loss, Noise-Induced | 1 | 2019 | 18 | 0.040 |
Why?
| | Kidney Medulla | 1 | 2019 | 31 | 0.040 |
Why?
| | Amino Acid Sequence | 4 | 2009 | 2154 | 0.040 |
Why?
| | Infliximab | 2 | 2012 | 108 | 0.040 |
Why?
| | Molecular Sequence Data | 4 | 2009 | 2929 | 0.040 |
Why?
| | Acute Disease | 1 | 2002 | 1028 | 0.040 |
Why?
| | Selection Bias | 1 | 2018 | 38 | 0.040 |
Why?
| | Organizational Case Studies | 1 | 2018 | 69 | 0.040 |
Why?
| | Patient Care Team | 1 | 2024 | 686 | 0.040 |
Why?
| | Health | 1 | 2018 | 81 | 0.030 |
Why?
| | Immunohistochemistry | 1 | 2002 | 1715 | 0.030 |
Why?
| | Transcription Factors | 1 | 2006 | 1739 | 0.030 |
Why?
| | Cities | 1 | 2018 | 143 | 0.030 |
Why?
| | Genetic Association Studies | 2 | 2010 | 372 | 0.030 |
Why?
| | Xanthine Oxidase | 1 | 2018 | 79 | 0.030 |
Why?
| | Quality of Life | 2 | 2012 | 3166 | 0.030 |
Why?
| | Polymerase Chain Reaction | 2 | 2011 | 1054 | 0.030 |
Why?
| | Lung Neoplasms | 1 | 2011 | 2637 | 0.030 |
Why?
| | Haplotypes | 2 | 2010 | 490 | 0.030 |
Why?
| | Fibrosis | 1 | 2000 | 547 | 0.030 |
Why?
| | Congresses as Topic | 1 | 2018 | 221 | 0.030 |
Why?
| | Uric Acid | 1 | 2018 | 166 | 0.030 |
Why?
| | Histocompatibility Testing | 2 | 2009 | 121 | 0.030 |
Why?
| | Observer Variation | 1 | 1997 | 354 | 0.030 |
Why?
| | Cost of Illness | 1 | 2018 | 319 | 0.030 |
Why?
| | Gene Frequency | 2 | 2010 | 481 | 0.030 |
Why?
| | Administration, Oral | 1 | 2018 | 847 | 0.030 |
Why?
| | Community Health Nursing | 1 | 2016 | 63 | 0.030 |
Why?
| | Sanitation | 1 | 2016 | 55 | 0.030 |
Why?
| | Antibody Formation | 1 | 1997 | 294 | 0.030 |
Why?
| | Poverty | 1 | 2019 | 523 | 0.030 |
Why?
| | Dyspnea | 3 | 2005 | 251 | 0.030 |
Why?
| | Collagen | 1 | 2018 | 455 | 0.030 |
Why?
| | Follow-Up Studies | 2 | 2021 | 5389 | 0.030 |
Why?
| | Antigens | 1 | 1997 | 347 | 0.030 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 3 | 2002 | 331 | 0.030 |
Why?
| | Siblings | 2 | 2006 | 195 | 0.030 |
Why?
| | Asthma | 2 | 2019 | 1767 | 0.030 |
Why?
| | Community Participation | 1 | 2016 | 132 | 0.030 |
Why?
| | Education, Nursing | 1 | 2016 | 93 | 0.030 |
Why?
| | Double-Blind Method | 2 | 2012 | 2025 | 0.030 |
Why?
| | Disease Susceptibility | 2 | 2000 | 346 | 0.030 |
Why?
| | Universities | 1 | 2016 | 451 | 0.020 |
Why?
| | Neural Tube Defects | 1 | 2014 | 65 | 0.020 |
Why?
| | Interleukin-2 | 2 | 2005 | 437 | 0.020 |
Why?
| | Infant, Low Birth Weight | 1 | 2014 | 153 | 0.020 |
Why?
| | Education, Medical | 1 | 2016 | 273 | 0.020 |
Why?
| | Cleft Palate | 1 | 2014 | 89 | 0.020 |
Why?
| | Mitochondria | 1 | 2019 | 983 | 0.020 |
Why?
| | Bronchiolitis | 1 | 1993 | 87 | 0.020 |
Why?
| | Lung Diseases | 1 | 1999 | 787 | 0.020 |
Why?
| | Politics | 1 | 2013 | 96 | 0.020 |
Why?
| | Enzyme-Linked Immunospot Assay | 1 | 2011 | 37 | 0.020 |
Why?
| | Epidemiological Monitoring | 1 | 2012 | 69 | 0.020 |
Why?
| | Maternal Exposure | 1 | 2014 | 213 | 0.020 |
Why?
| | Pneumonia | 1 | 1997 | 630 | 0.020 |
Why?
| | Genes, T-Cell Receptor beta | 2 | 2002 | 23 | 0.020 |
Why?
| | Pregnancy | 2 | 2014 | 7180 | 0.020 |
Why?
| | Finland | 1 | 2011 | 79 | 0.020 |
Why?
| | Fluorescent Antibody Technique | 1 | 2011 | 370 | 0.020 |
Why?
| | Qualitative Research | 1 | 2018 | 1659 | 0.020 |
Why?
| | Immunity, Cellular | 1 | 2012 | 272 | 0.020 |
Why?
| | Hazardous Substances | 1 | 2010 | 15 | 0.020 |
Why?
| | Netherlands | 1 | 2010 | 82 | 0.020 |
Why?
| | Inflammation | 1 | 2002 | 2877 | 0.020 |
Why?
| | Japan | 1 | 2010 | 143 | 0.020 |
Why?
| | Toxoplasma | 1 | 2010 | 49 | 0.020 |
Why?
| | Premature Birth | 1 | 2014 | 380 | 0.020 |
Why?
| | Salmonella enterica | 1 | 2010 | 59 | 0.020 |
Why?
| | HLA-A Antigens | 1 | 1989 | 52 | 0.020 |
Why?
| | United Kingdom | 1 | 2010 | 336 | 0.020 |
Why?
| | Antigen-Presenting Cells | 1 | 2009 | 160 | 0.020 |
Why?
| | HLA-B Antigens | 1 | 1989 | 56 | 0.020 |
Why?
| | Demography | 1 | 2009 | 284 | 0.020 |
Why?
| | Predictive Value of Tests | 2 | 2005 | 2111 | 0.020 |
Why?
| | Halogens | 1 | 2007 | 14 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2018 | 4556 | 0.020 |
Why?
| | Antineoplastic Agents | 1 | 2018 | 2192 | 0.020 |
Why?
| | Codon | 1 | 2007 | 94 | 0.020 |
Why?
| | Tuberculin | 1 | 2006 | 8 | 0.020 |
Why?
| | Mice, Inbred C57BL | 1 | 2018 | 5988 | 0.020 |
Why?
| | Cell Survival | 1 | 2009 | 1098 | 0.020 |
Why?
| | Placebos | 1 | 2006 | 192 | 0.020 |
Why?
| | Disinfection | 1 | 2007 | 129 | 0.010 |
Why?
| | Host-Pathogen Interactions | 1 | 2009 | 371 | 0.010 |
Why?
| | Hydrogen Peroxide | 1 | 2007 | 336 | 0.010 |
Why?
| | Heart Defects, Congenital | 1 | 2014 | 913 | 0.010 |
Why?
| | Eye | 1 | 2006 | 109 | 0.010 |
Why?
| | Cluster Analysis | 1 | 2007 | 519 | 0.010 |
Why?
| | Decision Making | 1 | 2013 | 974 | 0.010 |
Why?
| | Caspase 8 | 1 | 2005 | 47 | 0.010 |
Why?
| | Flow Cytometry | 1 | 2009 | 1172 | 0.010 |
Why?
| | Genetic Techniques | 1 | 2005 | 67 | 0.010 |
Why?
| | Free Radical Scavengers | 1 | 2005 | 81 | 0.010 |
Why?
| | Lymphocyte Count | 1 | 2005 | 164 | 0.010 |
Why?
| | Metalloporphyrins | 1 | 2005 | 66 | 0.010 |
Why?
| | Ultraviolet Rays | 1 | 2007 | 387 | 0.010 |
Why?
| | Chromosome Mapping | 1 | 2005 | 509 | 0.010 |
Why?
| | Caspases | 1 | 2005 | 232 | 0.010 |
Why?
| | Species Specificity | 1 | 2005 | 574 | 0.010 |
Why?
| | Abatacept | 1 | 2003 | 56 | 0.010 |
Why?
| | Adenocarcinoma | 1 | 2011 | 927 | 0.010 |
Why?
| | Genome-Wide Association Study | 1 | 2010 | 1406 | 0.010 |
Why?
| | Radioallergosorbent Test | 1 | 2003 | 3 | 0.010 |
Why?
| | Dose-Response Relationship, Immunologic | 1 | 2003 | 76 | 0.010 |
Why?
| | Thymidine | 1 | 2003 | 60 | 0.010 |
Why?
| | Mycobacterium tuberculosis | 1 | 2006 | 334 | 0.010 |
Why?
| | Skin Tests | 1 | 2003 | 94 | 0.010 |
Why?
| | Geography | 1 | 2003 | 203 | 0.010 |
Why?
| | Statistics as Topic | 1 | 2003 | 281 | 0.010 |
Why?
| | Genetic Testing | 1 | 2005 | 478 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2014 | 6424 | 0.010 |
Why?
| | Th1 Cells | 1 | 2002 | 139 | 0.010 |
Why?
| | Organ Specificity | 1 | 2002 | 312 | 0.010 |
Why?
| | Immunoconjugates | 1 | 2003 | 132 | 0.010 |
Why?
| | Mice, Inbred A | 1 | 2001 | 48 | 0.010 |
Why?
| | Autoantibodies | 1 | 1989 | 1497 | 0.010 |
Why?
| | Ceramics | 1 | 2001 | 22 | 0.010 |
Why?
| | Mice, Inbred C3H | 1 | 2001 | 251 | 0.010 |
Why?
| | Oxidative Stress | 1 | 2008 | 1339 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 2002 | 1047 | 0.010 |
Why?
| | Sequence Alignment | 1 | 2001 | 366 | 0.010 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2001 | 396 | 0.010 |
Why?
| | Dogs | 1 | 2001 | 437 | 0.010 |
Why?
| | Genes, T-Cell Receptor alpha | 1 | 1999 | 11 | 0.010 |
Why?
| | Gene Rearrangement, alpha-Chain T-Cell Antigen Receptor | 1 | 1999 | 21 | 0.010 |
Why?
| | Gene Rearrangement, beta-Chain T-Cell Antigen Receptor | 1 | 1999 | 27 | 0.010 |
Why?
| | Models, Animal | 1 | 2001 | 392 | 0.010 |
Why?
| | Forecasting | 1 | 2001 | 388 | 0.010 |
Why?
| | Clone Cells | 1 | 1999 | 266 | 0.010 |
Why?
| | Models, Statistical | 1 | 2003 | 677 | 0.010 |
Why?
| | Cell Movement | 1 | 2002 | 965 | 0.010 |
Why?
| | Skin | 1 | 2002 | 754 | 0.010 |
Why?
| | Models, Molecular | 1 | 2001 | 1618 | 0.010 |
Why?
| | Depression | 1 | 2005 | 1533 | 0.010 |
Why?
| | Bronchography | 1 | 1993 | 10 | 0.010 |
Why?
| | Cough | 1 | 1993 | 124 | 0.010 |
Why?
| | Bronchoscopy | 1 | 1993 | 227 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2005 | 6021 | 0.010 |
Why?
| | Bronchiectasis | 1 | 1993 | 112 | 0.010 |
Why?
|
|
Newman's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|